Tag:
PhRMA
Latest Headlines
Latest Headlines
Study: Countries angling to lure U.S. biopharma companies
Battelle reports that countries around the globe are boosting their investments in R&D and instituting innovation-friendly policies to attract biopharma outfits.
UPDATED: Biopharma lobby members pumped $49.5B into R&D
As the pharma industry rethinks the way it brings new drugs to market, drugmakers around the world haven't backed down from their multibillion-dollar research budgets.
Did Big Pharma scuttle an attempt to radically restructure the approval pathway?
Sen. Kay Hagan's proposal to set up an accelerated approval pathway for experimental medications hasn't been universally embraced by everyone in the biopharma industry.
Industry stymies effort to make it fund drug disposal program
Industry has temporarily swatted away the prospects for a California county's program that would have had it pay for the disposal of unused over-the-counter and prescription medications.
AARP finds nearly 26% increase in retail drug prices
AARP has unveiled its latest look at drug prices, and once again, the association of 50-plus Americans has found big increases.
HHS: Misbehaving drugmakers could lose patent rights
Big Pharma has paid big money to resolve big government investigations over the past 10 years--$8 billion, in fact, according to USA Today 's calculations. That's no secret to anyone who...
PhRMA's COPD pipeline report spotlights blockbuster hopefuls
Anyone looking for a basic primer on experimental COPD drugs should check out PhRMA's latest compilation of new drugs in the pipeline. The big trade group found 54 COPD studies underway, which
Startups ease access to online data on medical product side effects
The FDA has digested huge amounts of data on the hazardous effects of medical products for decades, and some entrepreneurs have set out to turn a profit from the information. Two recently launched...
Pfizer, PhRMA back SOPA amid online protests
With dozens of websites blocked in protest of new anti-piracy legislation, Pfizer ( $PFE ) and PhRMA are among the intellectual-property champions that are lobbying for, rather than against, the
PhRMA touts pediatric pipeline as it recruits lawmakers on legislation
Lest anyone forget that biopharma companies are in the business of finding new treatments to help people, the industry group PhRMA regularly assesses the number of pipeline drugs in development by
